Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271479 | 1.00 | CYP3A4 (0.56) | CYP3A4ATMBCL2L3MBTL1PTPN1 | |
| SCHEMBL7425238 | 0.98 | CYP3A4 (0.54) | CYP3A4ATMBCL2L3MBTL1PTPN1 | |
| SCHEMBL7425236 | 0.98 | CYP3A4 (0.54) | CYP3A4ATMBCL2L3MBTL1PTPN1 | |
| SCHEMBL271555 | 0.97 | CYP3A4 (0.54) | CYP3A4ATMBCL2L3MBTL1PTPN1 | |
| SCHEMBL271556 | 0.97 | CYP3A4 (0.54) | CYP3A4ATMBCL2L3MBTL1PTPN1 | |
| SCHEMBL271499 | 0.90 | ATM (0.64) | CYP3A4ATMSYK | |
| SCHEMBL273008 | 0.90 | ATM (0.64) | CYP3A4ATMSYK | |
| SCHEMBL271498 | 0.90 | ATM (0.64) | CYP3A4ATMSYK | |
| SCHEMBL272406 | 0.86 | ATM (0.59) | CYP3A4ATMBCL2PTPN1SYK | |
| SCHEMBL272806 | 0.86 | ATM (0.59) | CYP3A4ATMBCL2PTPN1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741938-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBVIE INC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524753-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2012-07-19 | — | — | US | disclosed |
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885ATM 4747/4885BCL2 4347/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885ATM 4747/4885BCL2 4347/4885 |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885ATM 4747/4885BCL2 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.